Severe Raynaud's phenomenon associated with interferon-beta therapy for multiple sclerosis: Case report;Fênomeno de Raynaud grave associado a terapia com interferon-beta para esclerose múltipla: Relato de caso

Arquivos de Neuro-Psiquiatria

Volumn 58, Issue 2 B, 2000, Pages 556-559

  Cruz, Boris Afonso ^a,b   De Queiroz, Eustáquio ^a   Nunes, Simone Vilela ^a   Cruz Filho, Achiles ^a   Campos, Gilberto Belisario ^a   De Carvalho Monteiro, Ernesto Lentz ^a   Crivellari, Humberto ^a  

^a Servico Neurol Hosp Governador I   (Brazil)

^b NONE   (Brazil)

Author keywords

Interferon ; Multiple sclerosis; Raynaud's phenomenon

Indexed keywords

ALPHA INTERFERON; ANTICOAGULANT AGENT; CORTICOSTEROID; CYCLOPHOSPHAMIDE; INTERFERON BETA SERINE; BETA INTERFERON; GLUCOCORTICOID; IMMUNOLOGICAL ADJUVANT; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DISEASE SEVERITY; DRUG SAFETY; FEMALE; HISTOPATHOLOGY; HUMAN; MULTIPLE SCLEROSIS; RAYNAUD PHENOMENON; SKIN MANIFESTATION; CHEMICALLY INDUCED DISORDER; DRUG COMBINATION; FINGER; MIDDLE AGED; NECROSIS; PATHOLOGY; SKIN BLOOD VESSEL DISORDER;

ADJUVANTS, IMMUNOLOGIC; ANTICOAGULANTS; DRUG THERAPY, COMBINATION; FEMALE; FINGERS; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-BETA; MIDDLE AGED; MULTIPLE SCLEROSIS; NECROSIS; RAYNAUD DISEASE; SKIN DISEASES, VASCULAR;

EID: 0034199294     PISSN: 0004282X     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0004-282x2000000300025     Document Type: Article

References (16)

1. Sadik AS, Miller JR. Multiple sclerosis. In Rowland LP. Merritt's textbook of Neurology. 9Ed. New York: Wiliams and Wilkins, 1995;804-825.
2. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis Ann Neurol 1996;39:285-294.
3. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MR1 Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995;45:1277-1285.
4. Poser CM, Patty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols, Ann Neurol 1983;13:227-231.
5. Durum SK, Oppenheim JJ. Proinflamatory cytokines and immunity. In Paul WE (ed). Fundamental immunology. New York: Raven Press, 1993:815-819.
6. Conlon KC, Urba WJ, Smith JW, et al. Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy. Cancer 1990;65:2237-2242.
7. Levesque MC, Ward FE, Douglas RJ, Weinberg JB. Interferon-β1A induced polyarthritis in a patient with the HLA-DRB12*0404 Allele. Arthritis Rheum 1999;42:569-573.
8. Bachmeyer C, Farge D, Gluckman E, et al. Raynaud's phenomenon and digital necrosis induced by interferon-alpha. Br J Dermatol 1996; 135: 481-483.
9. McMurray RW, Elbourne K. Hepatitis virus infection and autoimmunity. Semin Arthritis Rheum 1997;26:689-701.
10. Midgard R, Gronning M, Ruse T, Kvale G, Nyland H. Multiple sclerosis and chronic inflammatory diseases: a case-control study. Acta Neurol Scand 1996;93:322-328.
11. Alsalameh S, Manger B, Kern P, Kalden J. New onset of rheumatoid arthritis during, interferon b-1B treatment in a patient with multiple sclerosis: comment on the case report by Jabaily and Thompson [Letter]. Arthritis Rheum 1998;41:754.
12. Linden D. Severe Raynaud's phenomenon associated with interferon-β treatment for multiple sclerosis [Letter]. Lancet 1998;352:878-879.
13. Sonnenblick M, Rosin A. Cardiotoxicity of interferon. Chest 1991;99:557-561.
14. Tada H, Saitoh S, Nakagawa Y, et al. Ischemic colitis during interferon-alpha treatment for chronic active hepatitis C. J Gastroenterol 1996;31: 582-584.
15. Purvin VA. Anterior ischemic optic neuropathy secondary to interferon-alpha. Arch Ophthalmol 1995;113:1041-1044.
16. Guyer DR, Tiedman J, Yannuzzi L, et al. Ineterferon-associated retinopathy. Arch Ophthalmol. 1993;111:350-356.